PHC-019 Pharmacogenetics of Antiplatelet Agents: Towards Personalised Treatment?
نویسندگان
چکیده
منابع مشابه
Antiplatelet agents for the treatment and prevention of atherothrombosis.
The clinical pharmacology of antiplatelet drugs has been reviewed previously by the European Society of Cardiology (ESC) Task force and by the 8th American College of Chest Physicians (ACCP) Evidence-Based Clinical Practice Guidelines. Moreover, information on the efficacy and safety of antiplatelet drugs in the treatment and prevention of atherothrombosis is provided by collaborative meta-anal...
متن کاملAntiplatelet agents and heart
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706–17. [12] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (Caprie). Caprie steering committee. Lancet 1996;348: 1329–39. [13] Di Dedda U, Ranucci M, Baryshnikova E, Castelvecchio S. Thienopyridines resistance and recovery of pla...
متن کاملAntiplatelet agents and anaesthesia
Antiplatelet agents are increasingly being used in the management of all types of atherosclerotic disease, and, accordingly, patients on them are presenting more frequently for anaesthesia. Presentations range from elective patients taking aspirin as monotherapy for primary prevention of cardiovascular morbidity, to those maintained on multiple therapies requiring salvage surgery after a cardio...
متن کاملAntiplatelet agents and proton pump inhibitors – personalizing treatment
INTRODUCTION Antiplatelet therapy remains one of the cornerstones in the management of non-cardioembolic ischemic stroke. However, a significant percentage of patients have concomitant gastroesophageal reflux or peptic ulcer disease that requires acid-reducing medications, the most powerful and effective being the proton pump inhibitors (PPIs). Antiplatelet efficacy, at least in vivo, and parti...
متن کاملPerioperative management of antiplatelet agents.
Perioperative management of antiplatelet agents is a common challenge with the increased number of patients requiring long-term therapy following coronary stenting. Debate currently exists regarding if and when to discontinue antiplatelet therapy prior to elective surgery. The delicate balance between decreasing the risk of bleeding intraoperatively and minimizing the risk of stent thrombosis i...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: European Journal of Hospital Pharmacy
سال: 2013
ISSN: 2047-9956,2047-9964
DOI: 10.1136/ejhpharm-2013-000276.364